Project Summary: Lupus is a devastating disease where your immune system, normally in charge of defending you from infection, begins to attack your own cells. Patients with lupus can suffer damage to ...
WATERTOWN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Scientists at CeMM, the Medical University of Vienna, and the University of Lausanne succeeded for the first time in identifying and characterizing a new small molecule called "Feeblin", which can ...
BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart ...
Novel TROP2-targeted CAR T cells with high specificity and sustained efficacy for solid tumors in animal models. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback